Table 3.

Treatment-related AEs, ≥10% any grade in any arm.

Arms A + D + EArm BArm C
2L/3L D+T2L D2L T
(n = 71)(n = 24)(n = 12)
Adverse eventAny GradeGrade 3/4Any GradeGrade 3/4Any GradeGrade 3/4
Diarrhea12 (16.9)2 (2.8)1 (4.2)03 (25.0)1 (8.3)
Aspartate aminotransferase increased2 (2.8)0003 (25.0)1 (8.3)
Dyspnea4 (5.6)0003 (25.0)0
Fatigue14 (19.7)2 (2.8)2 (8.3)02 (16.7)1 (8.3)
Decreased appetite11 (15.5)1 (1.4)3 (12.5)01 (8.3)0
Colitis4 (5.6)3 (4.2)002 (16.7)2 (16.7)
Pruritus8 (11.3)0002 (16.7)0
Rasha9 (12.7)1 (1.4)002 (16.7)0
Alanine aminotransferase increased1 (1.4)1 (1.4)002 (16.7)0
Lipase increased2 (2.8)2 (2.8)002 (16.7)1 (8.3)
Dermatitis acneiform1 (1.4)0002 (16.7)1 (8.3)
Nausea6 (8.5)1 (1.4)1 (4.2)01 (8.3)0
Dry skin2 (2.8)0002 (16.7)0
Amylase increased2 (2.8)2 (2.8)002 (16.7)0
Vomiting4 (5.6)0001 (8.3)0
Weight decreased4 (5.6)00000
Hyperglycemia3 (4.2)2 (2.8)0000
Blood thyroid-stimulating hormone increased3 (5.8)00000
Hypothyroidism3 (5.8)00000
  • aPooled data for rash and rash maculopapular.